The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.
Squamous Cell Carcinoma of Esophagus
DRUG: Andrographis Paniculata
Symptomatic relief and quality of life after AP, Symptomatic relief of Dysphagia and quality of life after treatment Dysphagia measured by Dysphagia score Quality of Life measured by EORTC-QLQ-C30, 4 months
Difficulty to swallow, Difficulty to swallow by dysphagia grade 0 = able to eat normal diet / no dysphagia.

1. = able to swallow some solid foods
2. = able to swallow only semi solid foods
3. = able to swallow liquids only
4. = unable to swallow anything / total dysphagia, 4 months|Survival, Median Survival, up to 36 months|Adverse events, Rate of adverse events, up to 36 months|AP side effects, Side effects related to AP including

1. Gastrointestinal upset
2. Nausea and Vomiting
3. Allergy
4. Diarrhoea
5. Abdominal pain
6. Dizziness, 4 months
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.